Lisamarie Fahy - Omega Therapeutics Senior Operations
| OMGA Stock | USD 0.80 0.06 6.98% |
Executive
Lisamarie Fahy is Senior Operations of Omega Therapeutics
| Address | 20 Acorn Park Drive, Cambridge, MA, United States, 02140 |
| Phone | 617 949 4360 |
| Web | https://omegatherapeutics.com |
Omega Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2537) % which means that it has lost $0.2537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2915) %, meaning that it created substantial loss on money invested by shareholders. Omega Therapeutics' management efficiency ratios could be used to measure how well Omega Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.59. At present, Omega Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 120.2 M, whereas Total Assets are forecasted to decline to about 135.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Anna Gifford | Compass Therapeutics | N/A | |
| Avraham MD | Orchestra BioMed Holdings | 68 | |
| Juan Lorenzo | Orchestra BioMed Holdings | N/A | |
| MD MBA | Compass Therapeutics | 52 | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| Gopi MBA | Larimar Therapeutics | 53 | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Naseem MD | Olema Pharmaceuticals | 51 | |
| BSc MD | Aerovate Therapeutics | N/A | |
| Neil CPA | Compass Therapeutics | 57 | |
| Helen MD | Enliven Therapeutics | 61 | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Julie Dexter | Olema Pharmaceuticals | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Tim Smith | Pmv Pharmaceuticals | N/A | |
| Marc MD | Pmv Pharmaceuticals | N/A | |
| Geoffrey Mogilner | Olema Pharmaceuticals | N/A | |
| Jaya Goyal | PepGen | 56 | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| MSc MD | Centessa Pharmaceuticals PLC | 66 | |
Management Performance
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.25 |
Omega Therapeutics Leadership Team
Elected by the shareholders, the Omega Therapeutics' board of directors comprises two types of representatives: Omega Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Omega. The board's role is to monitor Omega Therapeutics' management team and ensure that shareholders' interests are well served. Omega Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Omega Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| JD Esq, Chief Secretary | ||
| Kevin McManus, Chief Officer | ||
| Kaan Certel, Chief Officer | ||
| Barbara Chan, Principal Office | ||
| Noubar Afeyan, CoFounder Chairman | ||
| Mahesh Karande, CEO President | ||
| Jennifer Nelson, Senior Research | ||
| Joshua MBA, Chief Officer | ||
| Lisamarie Fahy, Senior Operations | ||
| Sivakesava Sakhamuri, Senior Quality | ||
| Anthony Mullin, Chief Officer | ||
| Yan MD, Chief Officer | ||
| Eva Stroynowski, Senior Affairs | ||
| Charles ODonnell, VP Sciences | ||
| Thomas McCauley, Chief Officer | ||
| Joe Newman, Senior Discovery |
Omega Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Omega Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (7.77) % | ||||
| Current Valuation | 141.82 M | ||||
| Shares Outstanding | 55.37 M | ||||
| Shares Owned By Insiders | 1.62 % | ||||
| Shares Owned By Institutions | 90.42 % | ||||
| Number Of Shares Shorted | 6.38 M | ||||
| Price To Book | 3.82 X | ||||
| Price To Sales | 6.98 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Omega Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Omega Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Omega Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Omega Therapeutics Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omega Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.32) | Revenue Per Share 0.114 | Quarterly Revenue Growth 1.812 | Return On Assets (0.25) | Return On Equity (1.29) |
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Omega Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.